Key Takeaways from the KIT Inhibitors Market Report<\/b><\/p>\n Discover which indication is expected to grab the major KIT inhibitors market share @ KIT Inhibitors Market Report<\/a><\/b><\/p>\n KIT Inhibitors Market Dynamics<\/b><\/p>\n The KIT inhibitors market is shaped by a combination of growing clinical demand, limited therapeutic options, and ongoing advancements<\/b> in targeted therapies. KIT, a receptor tyrosine kinase, plays a crucial role in cell growth and survival, and its mutations are strongly linked to malignancies such as gastrointestinal stromal tumors (GIST), systemic mastocytosis, and certain leukemias. The rising incidence<\/b> of these cancers and the need for more effective treatments have fueled the demand for KIT inhibitors. However, the current landscape is dominated by a few branded drugs, such as AYVAKIT (avapritinib), QINLOCK (ripretinib), and ROMVIMZA (vimseltinib)<\/b>, with no generic options available, reflecting a relatively narrow competitive field.<\/p>\n A key market driver is the increasing understanding of KIT-driven oncogenesis <\/b>and the development of highly selective inhibitors<\/b> that can overcome resistance to first-generation therapies. For example, mutations in the KIT gene often lead to resistance against older drugs like imatinib, pushing the need for next-generation inhibitors with improved efficacy and tolerability. In addition, strategic collaborations, licensing agreements, and FDA fast-track designations<\/b> for KIT-targeting agents have accelerated innovation, further supporting market growth. Biopharmaceutical companies are also investing heavily in research to explore KIT inhibition beyond GIST, expanding the potential market size.<\/p>\n Despite these opportunities, the KIT inhibitors market faces notable challenges. The high cost of branded therapies and strict reimbursement policies<\/b> in several regions can limit patient access, especially in emerging economies. Moreover, the complexity of targeting KIT mutations<\/b>, which often co-occur with other genetic alterations, makes drug development challenging and leads to high attrition rates in clinical trials. Competition from alternative treatment modalities<\/b>, including immunotherapies and other targeted agents, also poses a threat to the growth of this niche segment.<\/p>\n Looking ahead, the KIT inhibitors market is expected to witness steady growth as novel agents enter the pipeline and existing drugs gain approvals for expanded indications. Personalized medicine approaches<\/b>, including genetic testing and biomarker-driven therapy selection, will play a critical role in shaping treatment protocols. Advances in drug design<\/b>, such as allosteric inhibitors and combination regimens targeting resistance pathways, are likely to create new opportunities, making this a dynamic and evolving therapeutic area over the next decade.<\/p>\n KIT Inhibitors Treatment Market\u00a0<\/b><\/p>\n The current landscape of US FDA-approved KIT inhibitors is relatively narrow, with only a few branded therapies available, such as ROMVIMZA (vimseltinib), AYVAKIT (avapritinib), and QINLOCK (ripretinib)<\/b>, and no generic alternatives on the market. This limited competition highlights the inherent challenges of effectively targeting KIT mutations.<\/p>\n ROMVIMZA is an oral kinase inhibitor with high selectivity for the colony-stimulating factor 1 receptor (CSF1R). Preclinical research has shown that vimseltinib inhibits CSF1R autophosphorylation, blocks ligand-stimulated signaling, and reduces the proliferation of CSF1R-positive cells. It is indicated for adults with symptomatic TGCT where surgical resection would likely result in major functional impairment or severe complications. In February 2025, the US FDA approved ROMVIMZA for this indication. Previously, in July 2024, the EMA accepted the marketing authorization application (MAA) for vimseltinib in TGCT. The drug is also being evaluated in a Phase II trial for chronic GvHD.<\/p>\n QINLOCK is a broad-spectrum tyrosine kinase inhibitor designed to target KIT and PDGFRA, including both wild-type and resistant primary and secondary mutations frequently seen in GIST. It also demonstrates in vitro activity against kinases such as PDGFRB, TIE2, VEGFR2, and BRAF. Clinically, QINLOCK is approved for adults with advanced GIST who have progressed after at least three prior kinase inhibitors, including imatinib, filling a critical therapeutic gap in later-line treatment. QINLOCK received FDA approval in May 2020, followed by European Commission approval in November 2021.<\/p>\n AYVAKIT is a potent and selective tyrosine kinase inhibitor that targets key activating mutations in KIT and PDGFRA, including KIT D816V and PDGFRA D842V, with sub-nanomolar to low nanomolar activity in preclinical studies. It effectively inhibits autophosphorylation and cell proliferation in KIT-driven and PDGFRA-resistant models. Clinically, AYVAKIT is approved for unresectable or metastatic GIST with PDGFRA exon 18 mutations (including D842V), as well as AdvSM and ISM, but its use is restricted in patients with platelet counts below 50\u00d710\u2079\/L. It was first approved by the FDA in January 2020 for adults with unresectable or metastatic GIST harboring PDGFRA exon 18 mutations, including D842V\u2014the first therapy to specifically target this mutation. The European Commission subsequently granted conditional marketing authorization under the name AYVAKYT in September 2020 for monotherapy in adults with unresectable or metastatic GIST carrying PDGFRA D842V mutations.<\/p>\n Learn more about the KIT inhibitors\u00a0@ KIT Inhibitors Analysis<\/a><\/b><\/p>\n Key Emerging KIT Inhibitors and Companies<\/b><\/p>\n A growing pipeline of KIT inhibitors is being investigated across a diverse set of indications beyond oncology, including CSU, multiple sclerosis, and GvHD. Prominent candidates such as barzolvolimab (CDX-0159), bezuclastinib (CGT9486), and elenestinib (BLU-263)<\/b>, among others, reflect this expanding therapeutic interest, signaling the potential of KIT-targeted therapies in addressing immune-mediated and inflammatory conditions.<\/p>\n Barzolvolimab <\/b>is a humanized monoclonal antibody that specifically targets the receptor tyrosine kinase KIT, effectively blocking its activity. By inhibiting KIT signaling, which regulates mast cell development, survival, and function, barzolvolimab tackles a critical driver of mast cell\u2013mediated inflammatory processes. This mechanism is especially significant in diseases like chronic urticaria, where abnormal mast cell activation is central to disease progression.<\/p>\n Barzolvolimab is in various stages of clinical development for multiple inflammatory disorders, including chronic spontaneous urticaria, chronic inducible urticaria, eosinophilic esophagitis, prurigo nodularis, and atopic dermatitis, with CSU being the most advanced program, currently in Phase III. At the EAACI Congress in June 2025, Celldex Therapeutics presented strong Phase II data showing durable complete responses and notable quality-of-life improvements at 76 weeks, extending well beyond the dosing period. Additional data revealed significant reductions in angioedema at 52 weeks, reinforcing barzolvolimab’s potential as a transformative therapy for CSU.<\/p>\n Bezuclastinib (CGT9486)<\/b>\u00a0is a highly selective and potent tyrosine kinase inhibitor (TKI) that targets the KIT D816V mutation, a primary driver in most systemic mastocytosis cases, as well as other KIT exon 17 mutations often found in advanced gastrointestinal stromal tumors. It is being developed for patients with non-advanced systemic mastocytosis (NonAdvSM), advanced systemic mastocytosis (AdvSM), and GIST. In February 2025, Cogent Biosciences presented data on the efficacy and safety of bezuclastinib in adult patients with NonAdvSM from the Phase II SUMMIT trial at the AAAAI Annual Meeting (February 28\u2013March 3, 2025).<\/p>\n Cogent Biosciences<\/b>\u00a0aims to achieve key milestones for bezuclastinib in 2025: release top-line Phase II SUMMIT trial data for NonAdvSM in July; report Phase II APEX trial results in AdvSM in the second half of the year; submit the first New Drug Application (NDA) by year-end; and present top-line results from the pivotal Phase III PEAK trial in imatinib-resistant GIST patients by late 2025.<\/p>\n Elenestinib (BLU-263)<\/b>\u00a0is an investigational oral, potent, and highly selective inhibitor of KIT D816V, designed for the treatment of indolent systemic mastocytosis (ISM) and other mast cell disorders. It is engineered to offer similar potency to avapritinib while minimizing off-target effects and central nervous system penetration. Elenestinib is currently being studied in the ongoing registration-enabling Phase II\/III HARBOR trial in ISM, which includes a dose-finding Part 1, a registration-focused Part 2, and a long-term treatment Part 3.<\/p>\n Top-line 12-week results from Part 1 of the HARBOR trial were announced in December 2022 and subsequently presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition in December 2023.<\/p>\n The anticipated launch of these emerging therapies is poised to transform the KIT inhibitors market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the KIT inhibitors market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.<\/p>\n To know more about KIT inhibitors clinical trials, visit @ KIT Inhibitors Treatment<\/a><\/b>\u00a0<\/p>\n KIT Inhibitors Overview<\/b><\/p>\n KIT inhibitors are a class of targeted therapies designed to block the activity of the KIT receptor tyrosine kinase, which plays a crucial role in cell proliferation, survival, and differentiation. Mutations or overactivation of KIT are implicated in several malignancies, including gastrointestinal stromal tumors and mastocytosis. By inhibiting KIT signaling, these drugs disrupt oncogenic pathways and help control tumor growth or abnormal cell proliferation.\u00a0<\/p>\n The therapeutic development of KIT inhibitors continues to evolve, with newer agents being designed to overcome resistance mechanisms associated with first-generation TKIs. Resistance often arises due to secondary mutations in the KIT gene, leading to reduced drug binding and diminished efficacy.\u00a0<\/p>\n Advanced KIT inhibitors have been developed to address these resistance mutations by offering broader and more potent inhibition across multiple KIT variants. Ongoing research is focused on combination therapies, improved selectivity, and minimizing adverse effects, aiming to expand the clinical utility of KIT inhibitors across a wider range of cancers and other KIT-mediated disorders.<\/p>\n KIT Inhibitors Epidemiology Segmentation<\/b><\/p>\n The KIT inhibitors market report proffers epidemiological analysis for the study period 2020\u20132034 in the 7MM, segmented into:<\/p>\n KIT Inhibitors Report Metrics<\/b><\/p>\n<\/td>\n Details<\/b><\/p>\n<\/td>\n<\/tr>\n Study Period<\/p>\n<\/td>\n 2020\u20132034<\/p>\n<\/td>\n<\/tr>\n KIT Inhibitors Report\u00a0Coverage<\/p>\n<\/td>\n 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]<\/p>\n<\/td>\n<\/tr>\n Key Indications Covered in the Report<\/p>\n<\/td>\n Systemic Mastocytosis, Gastrointestinal Stromal Tumor (GIST), Chronic Spontaneous Urticaria (CSU), Graft-versus-host Disease (GvHD), Tenosynovial Giant Cell Tumor (TGCT), Advanced Systemic Mastocytosis (AdvSM), Non-advanced Systemic Mastocytosis (NonAdvSM), Indolent Systemic Mastocytosis (ISM), and others<\/p>\n<\/td>\n<\/tr>\n Key KIT Inhibitors Companies<\/p>\n<\/td>\n Celldex Therapeutics, Cogent Biosciences, Blueprint Medicines, ONO Pharmaceutical (Deciphera Pharmaceuticals), Blueprint Medicines, and others<\/p>\n<\/td>\n<\/tr>\n Key KIT Inhibitors<\/p>\n<\/td>\n Barzolvolimab (CDX-0159), Bezuclastinib (CGT9486), Elenestinib (BLU-263), ROMVIMZA (vimseltinib), QINLOCK (ripretinib), AYVAKIT\/AYVAKYT (avapritinib), and others<\/p>\n<\/td>\n<\/tr>\n Scope of the <\/b>KIT Inhibitors<\/b>\u00a0Market Report<\/b><\/p>\n Discover more about KIT inhibitors in development @ KIT Inhibitors Clinical Trials<\/a><\/b><\/p>\n Table of Contents<\/b><\/p>\n 1<\/p>\n<\/td>\n Key Insights<\/p>\n<\/td>\n<\/tr>\n 2<\/p>\n<\/td>\n Report Introduction<\/p>\n<\/td>\n<\/tr>\n 3<\/p>\n<\/td>\n Executive Summary<\/p>\n<\/td>\n<\/tr>\n 4<\/p>\n<\/td>\n Key Events<\/p>\n<\/td>\n<\/tr>\n 5<\/p>\n<\/td>\n Market Forecast Methodology<\/p>\n<\/td>\n<\/tr>\n 6<\/p>\n<\/td>\n KIT Inhibitor Market Overview at a Glance in the 7MM<\/p>\n<\/td>\n<\/tr>\n 6.1<\/p>\n<\/td>\n Market Share (%) Distribution by Indication in 2024<\/p>\n<\/td>\n<\/tr>\n 6.2<\/p>\n<\/td>\n Market Share (%) Distribution by Indication in 2034<\/p>\n<\/td>\n<\/tr>\n 7<\/p>\n<\/td>\n KIT Inhibitor: Background and Overview<\/p>\n<\/td>\n<\/tr>\n 7.1<\/p>\n<\/td>\n Introduction<\/p>\n<\/td>\n<\/tr>\n 7.2<\/p>\n<\/td>\n Evolution of KIT Inhibitor<\/p>\n<\/td>\n<\/tr>\n 7.3<\/p>\n<\/td>\n Treatment<\/p>\n<\/td>\n<\/tr>\n 8<\/p>\n<\/td>\n Target Patient Pool<\/p>\n<\/td>\n<\/tr>\n 8.1<\/p>\n<\/td>\n Key Findings<\/p>\n<\/td>\n<\/tr>\n 8.2<\/p>\n<\/td>\n Assumptions and Rationale: 7MM<\/p>\n<\/td>\n<\/tr>\n 8.3<\/p>\n<\/td>\n Epidemiology Scenario in the 7MM<\/p>\n<\/td>\n<\/tr>\n 8.3.1<\/p>\n<\/td>\n Total Cases in Selected Indications for KIT Inhibitor in the 7MM<\/p>\n<\/td>\n<\/tr>\n 8.3.2<\/p>\n<\/td>\n Total Eligible Patient Pool in Selected Indications for KIT Inhibitor in the 7MM<\/p>\n<\/td>\n<\/tr>\n 8.3.3<\/p>\n<\/td>\n Total Treated Cases in Selected Indications for KIT Inhibitor in the 7MM<\/p>\n<\/td>\n<\/tr>\n 8.4<\/p>\n<\/td>\n The US<\/p>\n<\/td>\n<\/tr>\n 8.5<\/p>\n<\/td>\n EU4 and the UK<\/p>\n<\/td>\n<\/tr>\n 8.6<\/p>\n<\/td>\n Japan<\/p>\n<\/td>\n<\/tr>\n 9<\/p>\n<\/td>\n Marketed Therapies<\/p>\n<\/td>\n<\/tr>\n 9.1<\/p>\n<\/td>\n Key Cross Competition<\/p>\n<\/td>\n<\/tr>\n 9.2<\/p>\n<\/td>\n ROMVIMZA (vimseltinib): ONO Pharmaceutical (Deciphera Pharmaceuticals)<\/p>\n<\/td>\n<\/tr>\n 9.2.1<\/p>\n<\/td>\n Product Description<\/p>\n<\/td>\n<\/tr>\n 9.2.2<\/p>\n<\/td>\n Regulatory Milestones<\/p>\n<\/td>\n<\/tr>\n 9.2.3<\/p>\n<\/td>\n Others Developmental Activities<\/p>\n<\/td>\n<\/tr>\n 9.2.4<\/p>\n<\/td>\n Clinical Trials Information<\/p>\n<\/td>\n<\/tr>\n 9.2.5<\/p>\n<\/td>\n Safety and Efficacy<\/p>\n<\/td>\n<\/tr>\n 9.3<\/p>\n<\/td>\n QINLOCK (ripretinib): ONO Pharmaceutical (Deciphera Pharmaceuticals)<\/p>\n<\/td>\n<\/tr>\n 9.4<\/p>\n<\/td>\n AYVAKIT\/AYVAKYT (avapritinib): Blueprint Medicines<\/p>\n<\/td>\n<\/tr>\n List of drugs to be continued in the final report…<\/p>\n<\/td>\n<\/tr>\n 10<\/p>\n<\/td>\n Emerging Therapies<\/p>\n<\/td>\n<\/tr>\n 10.1<\/p>\n<\/td>\n Key Cross Competition<\/p>\n<\/td>\n<\/tr>\n 10.2<\/p>\n<\/td>\n Barzolvolimab (CDX-0159): Celldex Therapeutics<\/p>\n<\/td>\n<\/tr>\n 10.2.1<\/p>\n<\/td>\n Drug Description<\/p>\n<\/td>\n<\/tr>\n 10.2.2<\/p>\n<\/td>\n Others Developmental Activities<\/p>\n<\/td>\n<\/tr>\n 10.2.3<\/p>\n<\/td>\n Clinical Trials Information<\/p>\n<\/td>\n<\/tr>\n 10.2.4<\/p>\n<\/td>\n Safety and Efficacy<\/p>\n<\/td>\n<\/tr>\n 10.2.5<\/p>\n<\/td>\n Analyst’s View<\/p>\n<\/td>\n<\/tr>\n 10.3<\/p>\n<\/td>\n Bezuclastinib (CGT9486): Cogent Biosciences<\/p>\n<\/td>\n<\/tr>\n 10.4<\/p>\n<\/td>\n Elenestinib (BLU-263): Blueprint Medicines<\/p>\n<\/td>\n<\/tr>\n List of drugs to be continued in the final report…<\/p>\n<\/td>\n<\/tr>\n 11<\/p>\n<\/td>\n KIT Inhibitor: the 7MM Analysis<\/p>\n<\/td>\n<\/tr>\n 11.1<\/p>\n<\/td>\n Key Findings<\/p>\n<\/td>\n<\/tr>\n 11.2<\/p>\n<\/td>\n Key Market Forecast Assumptions<\/p>\n<\/td>\n<\/tr>\n 11.2.1<\/p>\n<\/td>\n Cost Assumptions and Rebates<\/p>\n<\/td>\n<\/tr>\n 11.2.2<\/p>\n<\/td>\n Pricing Trends<\/p>\n<\/td>\n<\/tr>\n 11.2.3<\/p>\n<\/td>\n Analogue Assessment<\/p>\n<\/td>\n<\/tr>\n 11.2.4<\/p>\n<\/td>\n Launch Year and Therapy Uptakes<\/p>\n<\/td>\n<\/tr>\n 11.3<\/p>\n<\/td>\n Market Outlook<\/p>\n<\/td>\n<\/tr>\n 11.4<\/p>\n<\/td>\n Attribute Analysis<\/p>\n<\/td>\n<\/tr>\n 11.5<\/p>\n<\/td>\n Total Market Size of KIT Inhibitor in the 7MM<\/p>\n<\/td>\n<\/tr>\n 11.6<\/p>\n<\/td>\n The US Market Size<\/p>\n<\/td>\n<\/tr>\n 11.6.1<\/p>\n<\/td>\n Total Market Size of KIT Inhibitor in the US<\/p>\n<\/td>\n<\/tr>\n 11.6.2<\/p>\n<\/td>\n Market Size of KIT Inhibitor by Therapies in the US<\/p>\n<\/td>\n<\/tr>\n 11.7<\/p>\n<\/td>\n EU4 and the UK Market Size<\/p>\n<\/td>\n<\/tr>\n 11.7.1<\/p>\n<\/td>\n Total Market Size of KIT Inhibitor in EU4 and the UK<\/p>\n<\/td>\n<\/tr>\n 11.7.2<\/p>\n<\/td>\n Market Size of KIT Inhibitor by Therapies in EU4 and the UK<\/p>\n<\/td>\n<\/tr>\n 11.8<\/p>\n<\/td>\n Japan Market Size<\/p>\n<\/td>\n<\/tr>\n 11.8.1<\/p>\n<\/td>\n Total Market Size of KIT Inhibitor in Japan<\/p>\n<\/td>\n<\/tr>\n 11.8.2<\/p>\n<\/td>\n Market Size of KIT Inhibitor by Therapies in Japan<\/p>\n<\/td>\n<\/tr>\n 12<\/p>\n<\/td>\n Unmet Needs<\/p>\n<\/td>\n<\/tr>\n 13<\/p>\n<\/td>\n SWOT Analysis<\/p>\n<\/td>\n<\/tr>\n 14<\/p>\n<\/td>\n KOL Views<\/p>\n<\/td>\n<\/tr>\n 15<\/p>\n<\/td>\n Market Access and Reimbursement<\/p>\n<\/td>\n<\/tr>\n 15.1<\/p>\n<\/td>\n The US<\/p>\n<\/td>\n<\/tr>\n 15.2<\/p>\n<\/td>\n EU4 and the UK<\/p>\n<\/td>\n<\/tr>\n 15.3<\/p>\n<\/td>\n Japan<\/p>\n<\/td>\n<\/tr>\n 16<\/p>\n<\/td>\n Acronyms and Abbreviations<\/p>\n<\/td>\n<\/tr>\n 17<\/p>\n<\/td>\n Bibliography<\/p>\n<\/td>\n<\/tr>\n Related Reports<\/b><\/p>\n Gastrointestinal Stromal Tumor Market<\/a><\/b><\/p>\n Gastrointestinal Stromal Tumor Market Insights, Epidemiology, and Market Forecast \u2013 2034 <\/b>report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key GIST companies, including Jiangsu Hengrui Medicine, Daiichi Sankyo Company, Cogent Biosciences, Advenchen Laboratories, AB Science, Immunicum AB, Novartis, Bristol-Myers Squibb, Hanmi Pharmaceutical Company Limited, Ascentage Pharma, Array BioPharma, Plexxikon, Arog Pharmaceuticals, Xencor Inc., DNAtrix Inc., Onyx Pharmaceuticals, Exelixis, Allarity Therapeutics, Theseus Pharmaceuticals, IDRx Inc., Allarity Therapeutics,<\/b> among others.<\/p>\n Chronic Spontaneous Urticaria Market<\/a><\/b><\/p>\n Chronic Spontaneous Urticaria Market Insights, Epidemiology, and Market Forecast \u2013 2034 <\/b>report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key CSU companies, including Celldex Therapeutics, Novartis, Sanofi, Incyte, Jasper Therapeutics, InflaRx, Evommune, Otsuka Holdings (Taiho Pharmaceutical),<\/b> among others.<\/p>\n Graft Versus Host Disease Market<\/a><\/b><\/p>\n Graft Versus Host Disease Market Insights, Epidemiology, and Market Forecast \u2013 2034 <\/b>report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key GvHD companies, including CSL Behring, Equillium, Biocon, MaaT Pharma, REGiMMUNE, ReAlta Life Sciences, Ono Pharmaceutical (Deciphera Pharmaceuticals), Medsenic, BioSenic, ASC Therapeutics, Cynata Therapeutics, Evive Biotech (Yifan Pharmaceutical), Ironwood, medac,<\/b> among others.<\/p>\n Systemic Mastocytosis Market<\/a><\/b><\/p>\n Systemic Mastocytosis Market Insights, Epidemiology, and Market Forecast \u2013 2034 <\/b>report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key systemic mastocytosis\u00a0companies, including AB Sciences, Blueprint Medicines, Patara Pharma, Seagen Inc., GT Biopharma, Deciphera Pharmaceuticals, Novartis Oncology,<\/b> among others.<\/p>\n About\u00a0DelveInsight<\/b><\/p>\n DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.\u00a0Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform\u00a0PharmDelve.<\/b><\/p>\n Contact Us\n
\n
\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n
\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n
<\/b>Shruti Thakur
[email\u00a0protected]<\/a>
+14699457679<\/p>\n
![\"\"](\"https:\/\/rt.prnewswire.com\/rt.gif?NewsItemId=IO41612&Transmission_Id=202507311731PR_NEWS_USPR_____IO41612&DateId=20250731\")
<\/p>\n","protected":false},"excerpt":{"rendered":"The KIT inhibitors market remains highly competitive, driven by established players such as ONO Pharmaceutical and Blueprint Medicines,…\n","protected":false},"author":2,"featured_media":39492,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[3091],"tags":[51,22427,22428,2441,16,15],"class_list":{"0":"post-307590","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-markets","8":"tag-business","9":"tag-delveinsight-business-research","10":"tag-llp","11":"tag-markets","12":"tag-uk","13":"tag-united-kingdom"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@uk\/114950036725508292","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/307590","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/comments?post=307590"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/posts\/307590\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media\/39492"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/media?parent=307590"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/categories?post=307590"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/uk\/wp-json\/wp\/v2\/tags?post=307590"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}